Welcome to our dedicated page for Nexgel Wt Exp 120126 SEC filings (Ticker: NXGLW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings related to NEXGEL, Inc. (NASDAQ: NXGL, warrants: NXGLW). Through these documents, investors can review how the company reports its financial condition, capital structure, governance decisions and material events in an official regulatory format.
NEXGEL’s periodic reports, such as Forms 10-K and 10-Q, contain audited or reviewed financial statements, including balance sheets, statements of operations and cash flows, along with management’s discussion of revenue from contract manufacturing and consumer branded products, gross profit, operating expenses and net loss. These filings also provide details on assets such as cash, inventory, goodwill, intangibles and property and equipment, and on liabilities including accounts payable, notes payable and lease obligations.
The company’s current reports on Form 8-K document specific material events. Recent 8-K filings describe the release of quarterly financial results and related investor presentations, the entry into subscription agreements for a registered direct offering and concurrent private placement of unregistered warrants, and additional private placement transactions with accredited investors. Other 8-Ks report on the expansion of NEXGEL’s partnership with STADA Arzneimittel AG and on the outcomes of the 2025 Annual Meeting of Stockholders, including director elections, amendments to the 2019 Long-Term Incentive Plan, advisory votes on executive compensation and the ratification of the independent auditor.
Filings related to equity and warrant issuances outline the terms of registered offerings, private placements and unregistered warrants, including exercise prices, terms, beneficial ownership limitations and registration obligations for warrant shares. These documents also describe the role and compensation of placement agents and the use of exemptions from registration under the Securities Act.
On this page, Stock Titan pairs the raw SEC filings with AI-powered summaries that highlight key points, such as changes in capital structure, outcomes of shareholder votes, and the nature of material agreements. Users can quickly identify which filings contain quarterly results, which relate to financings or partnerships, and which address governance and compensation matters, while still having direct access to the full text as filed on EDGAR.
NexGel director Jerome B. Zeldis received a stock option grant on June 25, 2025 for 30,000 shares of common stock at an exercise price of $2.32 per share. The options were granted under the company's 2019 Long-Term Incentive Plan for board service through the 2026 Annual Meeting.
Key terms of the stock option grant:
- Vesting schedule: Equal monthly installments of 2,500 shares over 12 months starting July 31, 2025
- Expiration date: June 25, 2035
- Exercise price: $2.32 per share
- Accelerated vesting provision in case of Change in Control
This Form 4 filing indicates continued alignment of director compensation with shareholder interests through equity-based incentives. The 10-year exercise period and monthly vesting schedule are typical for director equity compensation plans.